These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22531721)

  • 1. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.
    Guzzo F; Bellone S; Buza N; Hui P; Carrara L; Varughese J; Cocco E; Betti M; Todeschini P; Gasparrini S; Schwartz PE; Rutherford TJ; Angioli R; Pecorelli S; Santin AD
    Int J Gynecol Pathol; 2012 May; 31(3):211-21. PubMed ID: 22498937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
    Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
    Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
    Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
    Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
    Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
    Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis.
    Tang G; Pan L; Wang Z; Zhu H; Yang Y; Wang Z; Yue H; Shi Y; Wu D; Jiang Z; Jiang D
    Int Immunopharmacol; 2023 Jan; 114():109450. PubMed ID: 36446233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
    Zhao WP; Zhu B; Duan YZ; Chen ZT
    Oncol Rep; 2009 Jun; 21(6):1405-11. PubMed ID: 19424617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
    Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.